PolymarketCheck availabilityNo KYC2% feeVerified resolution dataFairly calibratedCurrent implied probability
Yes 87.1%+1.0pt
Market quality
74 / 100
Medium quality24h Volume
$18K
Liquidity
$4.5K
Medium liquidityBid / Ask
87.0% / 88.0%
Spread
1.0 pt
Tight spreadComments
0
Market data
Updated 13 minutes ago
Aug 19, 26, 6:47 PMJun 30, 27, 11:59 PM
Trends
Rules
This market will resolve to "Yes" if it is officially announced that a Biologics License Application (BLA) for intismeran autogene has been submitted to the U.S. Food and Drug Administration (FDA), or that the FDA has accepted such an application for review, by June 30, 2027, 11:59 PM ET.
- Otherwise, this market will resolve to "No".
- Intismeran autogene refers to the individualized neoantigen therapy developed by Moderna and Merck and evaluated in the Phase 3 INTerpath-001 trial (NCT05933577), also known as mRNA-4157 and V940, together with any brand, trade, or nonproprietary name later assigned to that product, as well as any renamed or modified version that the relevant company or the FDA identify as the same product or a direct continuation of the V940/mRNA-4157 program.
- A qualifying application must seek FDA licensure of intismeran autogene through a Biologics License Application (BLA).
- An original BLA or a resubmission of such a BLA following FDA action will qualify.
- The application may cover any indication.
Frequently asked questions
- What are the current odds for Skin cancer vaccine BLA submitted by June 30, 2027??
- Polymarket prices Yes at 87% as of August 21, 2026.
- When does Skin cancer vaccine BLA submitted by June 30, 2027? resolve?
- Skin cancer vaccine BLA submitted by June 30, 2027? is scheduled to resolve on June 30, 2027.
- How is Skin cancer vaccine BLA submitted by June 30, 2027? settled?
- Polymarket settles this market as follows: This market will resolve to "Yes" if it is officially announced that a Biologics License Application (BLA) for intismeran autogene has been submitted to the U.S. Food and Drug Administration (FDA), or that the FDA has accepted such an application for review, by June 30, 2027, 11:59 PM ET.
